Long-Term Safety of Mometasone Furoate/Formoterol Combination for Treatment of Patients with Persistent Asthma

References

• Murphy KR. Asthma: versatile treatment for a variable disease. J Asthma 2005; 42:149–157.
   PubMed Web of Science ®Google Scholar
• Bernstein DI. ABCs of asthma. Clin Cornerstone 2008; 8:9–25.
   PubMedGoogle Scholar
• Dougherty RH, Fahy JV. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype. Clin Exp Allergy 2009; 39:193–202.
   PubMed Web of Science ®Google Scholar
• Fanta CH. Asthma. N Engl J Med. 2009; 360:1002–1014.
   Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. Available at: http://www.ginasthma.com/Guidelineitem.asp??l1=2&l2=1&intId=1561. Accessed July 29, 2010.
   Google Scholar
• National Heart Lung and Blood Institute – National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed July 29, 2010.
   Google Scholar
• Tan RA, Corren J. Mometasone furoate in the management of asthma: a review. Ther Clin Risk Manag 2008; 4:1201–1208.
   PubMedGoogle Scholar
• Bernstein DI, Berkowitz RB, Chervinsky P, Dvorin DJ, Finn AF, Gross GN, Karetzky M, Kemp JP, Laforce C, Lumry W, Mendelson LM, Nelson H, Pearlman D, Rachelefsky G, Ratner P, Repsher L, Segal AT, Selner JC, Settipane GA, Wanderer A, Cuss FM, Nolop KB, Harrison JE. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 1999; 93:603–612.
   PubMed Web of Science ®Google Scholar
• Fish JE, Karpel JP, Craig TJ, Bensch GW, Noonan M, Webb DR, Silverman B, Schenkel EJ, Rooklin AR, Ramsdell JW, Nathan R, Leflein JG, Grossman J, Graft DF, Gower RG, Garay SM, Frigas E, Degraff AC, Bronsky EA, Bernstein DI, Berger W, Shneyer L, Nolop KB, Harrison JE. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol 2000; 106:852–860.
   PubMed Web of Science ®Google Scholar
• Kemp JP, Berkowitz RB, Miller SD, Murray JJ, Nolop K, Harrison JE. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol 2000; 106:485–492.
   PubMed Web of Science ®Google Scholar
• Nayak AS, Banov C, Corren J, Feinstein BK, Floreani A, Friedman BF, Goldsobel A, Gottschlich GM, Hannaway PJ, Lampl KL, Lapidus RJ, Lawrence M, Lumry W, Munk Z, Pearlman D, Scardella AT, Schenkel EJ, Segal AT, Segall N, Silverman B, Shneyer L, Nolop KB, Harrison JE. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol 2000; 84:417–424.
   PubMed Web of Science ®Google Scholar
• Nathan RA, Nayak AS, Graft DF, Lawrence M, Picone FJ, Ahmed T, Wolfe J, Vanderwalker ML, Nolop KB, Harrison JE. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol 2001; 86:203–210.
   PubMed Web of Science ®Google Scholar
• D'Urzo A, Karpel JP, Busse WW, Boulet LP, Monahan ME, Lutsky B, Staudinger H. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr Med Res Opin 2005; 21:1281–1289.
   PubMed Web of Science ®Google Scholar
• Bensch GW, Prenner B, Berkowitz R, Galant S, Ramsdell J, Lutsky B. Once-daily evening administration of mometasone furoate in asthma treatment initiation. Ann Allergy Asthma Immunol 2006; 96:533–540.
   PubMed Web of Science ®Google Scholar
• Karpel JP, Nayak A, Lumry W, Craig TJ, Kerwin E, Fish JE, Lutsky B. Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma. Respir Med 2007; 101:628–637.
   PubMed Web of Science ®Google Scholar
• Bensch G, Lapidus RJ, Levine BE, Lumry W, Yegen U, Kiselev P, Della Cioppa G. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol 2001; 86:19–27.
   PubMed Web of Science ®Google Scholar
• Pleskow W, LaForce CF, Yegen U, Matos D, Della Cioppa G. Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial. J Asthma 2003; 40:505–514.
   PubMed Web of Science ®Google Scholar
• LaForce C, Prenner BM, Andriano K, Lavecchia C, Yegen U. Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma. J Asthma 2005; 42:101–106.
   PubMed Web of Science ®Google Scholar
• Dahl R, Creemers JP, Van Noord J, Sips A, Della Cioppa G, Thomson M, Andriano K, Kottakis J, Fashola T. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma. Respiration 2004; 71:126–133.
   PubMed Web of Science ®Google Scholar
• Reynolds NA, Lyseng-Williamson KA, Wiseman LR. Inhaled salmeterol/fluticasone propionate: a review of its use in asthma. Drugs 2005; 65:1715–1734.
   PubMed Web of Science ®Google Scholar
• Lasserson TJ, Cates CJ, Ferrara G, Casali L. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev 2008; CD004106.
   Web of Science ®Google Scholar
• Chylack LT, Jr., Wolfe JK, Singer DM, Leske MC, Bullimore MA, Bailey IL, Friend J, McCarthy D, Wu SY. The lens opacities classification system III. The longitudinal study of cataract study group. Arch Ophthalmol 1993; 111:831–836.
   Google Scholar
• Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006; 28:1042–1050.
   PubMed Web of Science ®Google Scholar
• Morice AH, Hochmuth L, Ekelund J, Thorén A, Puterman AS. Comparable long-term safety and efficacy of a novel budesonide/formoterol pressurized metered-dose inhaler versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma. Pulm Pharmacol Ther 2008; 21:32–39.
   PubMed Web of Science ®Google Scholar
• Peters SP, Prenner BM, Mezzanotte WS, Martin P, O'Brien CD. Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients. Allergy Asthma Proc 2008; 29:499–516.
   PubMed Web of Science ®Google Scholar
• Nathan RA, Nolte H, Pearlman DS. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 μg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc 2010; 31:269–279.
   PubMed Web of Science ®Google Scholar
• Weinstein S, Corren J, Murphy K, Nolte H, White M. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 μg and 400/10 μg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. Allergy Asthma Proc 2010; 31:280–289.
   PubMed Web of Science ®Google Scholar
• Barnes NC. The properties of inhaled corticosteroids: similarities and differences. Prim Care Respir J 2007; 16:149–154.
   PubMedGoogle Scholar
• Meltzer EO, Wenzel S. The efficacy and safety of mometasone furoate delivered via a dry powder inhaler for the treatment of asthma. J Asthma 2006; 43:765–772.
   PubMed Web of Science ®Google Scholar
• Broadley KJ. Beta-adrenoceptor responses of the airways: for better or worse? Eur J Pharmacol 2006; 533:15–27.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Moral VP, Marcos LG, Castro-Rodriguez JA. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Pulm Pharmacol Ther 2009; 22:9–19.
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159:941–955.
   PubMed Web of Science ®Google Scholar
• Allen DB. Effects of inhaled steroids on growth, bone metabolism, and adrenal function. Adv Pediatr 2006; 53:101–110.
   PubMedGoogle Scholar
• D'Urzo A. Mometasone furoate dry-powder inhaler for the control of persistent asthma. Expert Opin Pharmacother 2007; 8:2871–2884.
   PubMed Web of Science ®Google Scholar
• Karpel JP, Nelson H. Mometasone furoate dry powder inhaler: a once-daily inhaled corticosteroid for the treatment of persistent asthma. Curr Med Res Opin 2007; 23:2897–2911.
   PubMed Web of Science ®Google Scholar
• Chylack LT, Jr., Gross GN, Pedinoff A. A randomized, controlled trial to investigate the effect of ciclesonide and beclomethasone dipropionate on eye lens opacity. J Asthma 2008; 45:893–902.
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Allen D, Milanowski J, Kalev I, Willits L, Davies P. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1–3 years with recurrent wheezing. Pediatrics 2004; 113:e87–e94.
   Web of Science ®Google Scholar
• Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJH, Pauwels RA, Pedersen SE. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004; 170:836–844.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl C, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337:1405–1411.
   PubMed Web of Science ®Google Scholar
• Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010; 362:1169–1171.
   PubMed Web of Science ®Google Scholar